Printer Friendly

CALGENE FILES SUIT AGAINST ENZO BIOCHEM

 DAVIS, Calif., Feb. 5 /PRNewswire/ -- Calgene Inc. (NASDAQ-NMS: CGNE) announced that it has filed suit against Enzo Biochem Inc. (AMEX: ENZ), in the U.S. District Court, Eastern Distric of California. Calgene is seeking to have the pending U.S. Enzo anti-sense patent declared invalid and to be awarded damages for statements which Enzo representatives have made to the public regarding the breadth of its patent and the revenues that it would realize from Calgene as a licensee under the patent.
 Enzo is the exclusive licensee of pending patent applications relating to anti-sense technology filed by the Research Foundation of the State University of New York (SUNY). On numerous occasions over the past several months, Enzo has made statements that the U.S. Patent and Trademark Office has allowed broad claims in the Enzo patent that would cover agricultural applications of the technology, including the FLAVR SAVR(TM) tomato.
 Roger Salquist, Calgene's chairman and chief executive officer said, "We could not sit patiently any longer allowing Enzo to continue to threaten Calgene with their patent position when Calgene does not consider the Enzo patent to be valid and we certainly don't plan to alter our commercialization plan for our FLAVR SAVR(TM) tomatoes based upon Enzo's patent."
 Calgene's own anti-sense patent, U.S. Patent 5,107,065, directed to anti-sense in plants issued in April 1992. It was granted after specific consideration by the U.S. Patent Examiner of the work done at SUNY in bacterial cells and reference to the then published European counterpart of the Enzo U.S. patent. Calgene's issued patent is not involved in the lawsuit.
 The litigation is expected to take several years to resolve. "By instituting this suit, we are confronting the Enzo issue as quickly as possible," noted Salquist. Calgene's fresh-produce subsidiary, Calgene Fresh, plans to commercially introduce the FLAVR SAVR(TM) tomato later this year; it does not expect that marketing of the tomato will be affected by the Enzo patent or the litigation.
 -0- 2/5/93
 /CONTACT: Roger Salquist, chariman and chief executive officer of Calgene, 916-753-6313/
 (CGNE ENZ)


CO: Calgene Inc.; Enzo Biochem Inc. ST: California IN: MTC FOD SU:

GT-TM -- SF006 -- 3564 02/05/93 13:29 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 5, 1993
Words:370
Previous Article:STATEMENT BY DUQUESNE LIGHT COMPANY
Next Article:COSTCO PROPOSES OUTLET ON 13.5-ACRE TRIAD PARK PARCEL
Topics:


Related Articles
94 PERCENT OF ENZO BIOCHEM DEBENTURES CONVERTED TO STOCK; ENZO GAINS $32.5 MILLION IN NET WORTH FROM $28.2 MILLION CONVERSION
U.S. PATENT OFFICE NOTIFIES ENZO BIOCHEM OF PATENT ALLOWANCE FOR GENETIC ANTISENSE TECHNOLOGY
CALGENE CLARIFIES MISLEADING PRESS REPORTS ON ENZO LITIGATION
CALGENE SIGNS ANTISENSE PATENT LICENSE WITH THE FRED HUTCHINSON CANCER RESEARCH CENTER
CALGENE PREVAILS IN ENZO PATENT LITIGATION; CALGENE PLANT ANTISENSE PATENT HELD VALID
CALGENE ANNOUNCES SECOND QUARTER FINANCIAL RESULTS
CALGENE ASKS COURT TO CLARIFY ANTISENSE LITIGATION RULING
Gene Therapy for HIV to Get First Test in Humans; Enzo Therapeutics Files IND with FDA for Testing at University of California, San Francisco
Enzo Biochem files suit against eight Life Science companies. (Executive Briefing).
Court dismisses claims in Enzo Biotech v. Applied Biosystems.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters